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„High quality scientific evidence is needed when professionals  
intervene in the lives of other people“   
(Sir Iain Chalmers) 
 
There have been a lot of myths and misconceptions about the nature of 
addiction. When science began to study addiction in the 1930s, people addicted 
to drugs were thought to be morally flawed and lacking in willpower (NIDA 
2010). Those views shaped society's responses to drug abuse, treating it as a 
moral failing rather than a health problem, which led to an emphasis on punitive 
rather than preventative and therapeutic actions. Recent scientific research has 
shown that drug abuse and addiction is a chronic relapsing brain disease that is 
characterized by compulsive drug seeking and use, despite harmful con-
sequences (Ersche et al., 2012; Kasanetz et al., 2010; Leshner 1997).  
Drug abuse and addiction are substantial threats to the public good, besides 
affecting public health generating crime, disorder, family break ups and 
community decay (Strang et al., 2012). Contemporary drug policy aims through 
a broad range of regulations, enforcements and laws to promote the public 
good, but the effectiveness of these policy measures is rarely informed by 
scientific evidence. From the perspective of public health, there is need for a 
system that is more in line with the risks that different drugs pose, and shows an 
understanding of the effects of different regulatory approaches on drug use and 
drug-related harms (Room & Reuter 2012). Here scientific research can make 
important contributions to inform and guide the selection of policies, in order to 
prevent the initiation of drug use, help problem users change their behavior to 
reduce the consequences of their drug use and control the supply of illicit drug 
use (Strang et al., 2012).   
The use of drugs has grown during the past two decades in the general 
population and among schoolchildren in Estonia (ESPAD Report 1995; ESPAD 
Report 1999; ESPAD Report 2003; ESPAD Report 2007; ESPAD Report 2011; 
Hansson 2009). In addition, Estonia has one of the highest rates of estimated 
injecting drug use prevalence in Eastern Europe, which is the main driver of the 
HIV epidemic, causing a high number of drug-related deaths among young 
males and and entailing high social and health welfare costs to society (Mathers 
et al., 2008). Why injecting drug use in particular is posing a problem to such an 
extent and severity in Estonia is open to interpretation and further rigorous 
research. This thesis is contributing to the existing knowledge base by 
describing the phenomenon of injecting drug use and injecting drug user`s 
behavior, the drug users population needs for health and prevention services and 
implications for drug policy. Further, this work analyzes utilization of existing 
harm reduction interventions (measures to minimize drug related damage) 
targeted at injecting drug users and the introduction of possible new inter-
ventions. 
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2. REVIEW OF LITERATURE 
 
2.1. Drug use as a dependence disorder  
2.1.1. Concepts related to drug use and abuse 
People have been using drugs for thousands of years for a variety of purposes, 
depending on various socio-cultural and biological factors. Although drugs 
affect our lives every day, such as when using medications or via news 
reporting in the media, defining drug itself can be complicated. The concept of 
“drug” has varied usage, in medicine it refers to any substance with the 
potential to prevent or cure disease or enhance physical or mental welfare; in 
pharmacology it means any chemical agent that alters the biochemical or 
physiological processes of tissues or organisms, in the context of international 
drug control, “drug” means any substance in Schedule I and II of the 1961 and 
1971 Convention, whether natural or synthetic origin (UNODC 2003).  
Feeling happiness and peacefulness is a complicated art and one of the 
easiest and perhaps the most rapid way to alter one`s moods and feelings is to 
affect brain with chemical substances (Harro 2006). Drug use can be the use of 
any drug, a headache pill, a cup of coffee, a glass of wine, a cigarette – they all 
affect human brain and behaviour. The drug abuse begins when drug use is 
starting to cause problems, i.e. either physical, psychological, legal or social 
harms to the user and/or to others affected by the drug users’ behaviour (Maisto 
et al., 1999). It is not clear, why drug use becomes the centre of individual`s life 
and means a continuous and deepening process for some people, but not for 
others. There have been loads of studies researching the pathways of 
dependence, whether it is genetically or neurobiologically determined, cognitive 
or behavioral disorder or of psychosocial origin.  
Several substance abuse classifications are available: ie. (1) the International 
Classification of Diseases and Health Problems – ICD; (2) American 
Psychiatric Association`s criteria for Diagnostic and Statistical Manual of 
Mental Disorders – DSM; (3) based on from which the treatment community 
view drug abuse (i.e. a moral, psychological or disease perspective); (4) the type 
of drug used (opioids, stimulants); or (5) the route of administration (i.e. 
injection drug use) (American Psychiatric Association 2000; EMCDDA 2009; 
West & Hardy 2006; World Health Organization 1992). Irrespective of different 
classifications in defining dependence the main characteristic is a strong desire, 
often overpowering, to take the psychoactive drugs (which may or may not have 
been medically prescribed), alcohol, or tobacco, while other parts of life will be 
left aside.  
This study defines “drug use” as those uses of psychotropic substance(s) for 




2.1.2. Drug use epidemiology research 
The effective prevention of health problems and other consequences of 
substance use requires information on the prevalence, characteristics and 
patterns of use, together with information on the problems associated with that 
use. Epidemiologic research plays a critical public health role by generating 
and providing evidence to estimate the magnitude, impact, and risk of drug 
abuse and related problems in a population, and to lay the foundation for 
developing strategies to prevent drug abuse, plan and evaluate drug abuse 
services, and suggest new areas for basic, clinical, and treatment research.   
Specific research areas of particular interest include but are not limited to 
the following:  
1. natural history, current and emergent drug abuse trends (assess and exa-
mine rates (e.g., prevalence, incidence) emerging and current patterns, and 
trends of drug use, abuse, addiction, morbidity, mortality and associated 
social and behavioral consequences (e.g., crime, violence, sexually trans-
mitted infections such as HIV, and other co-morbidities) in general and 
defined populations, with special attention to health disparity issues);  
2. studies of the origins and trajectories of drug use, abuse, and addiction  
(developmental trajectories: etiology, vulnerability, co-morbidity, genetics, 
course); 
3. social epidemiology (studies of the dynamic multi-level interaction among 
social environmental and individual-level factors in contributing to and/or 
protecting against drug use, abuse, and addiction and associated be-
havioral, social, and health outcomes across the life course);  
4. public health policy (studies to understand the effects of changing federal, 
state, or local laws, regulations and policies on the epidemiology of drug 
use which have the potential to inform future policy decisions); 
5. methodological (e.g., studies to compare the effect of different methods on 
data quality and on data collection) and measurement studies (e.g., studies 
assessing the accuracy of alternative methods for the survey measurement 
of drug use) (Babor et al., 2010; Sloboda 2005). 
 
 
2.1.3. Drug use in the general population 
Global trends in prevalence rates of drug use have remained generally stable 
over the last decade; UNODC has estimated 149 to 271 million people aged 15–
64 years, approximately 5% used an illicit drug at least once in 2009/2010 
(UNODC 2011). It is estimated that over one in five of all 15–64 year-olds has 
used cannabis at least once in their lifetime on average in European countries 
(EMCDDA 2011a). Lifetime prevalence of amphetamines use among young 
adults (15–34 years) varied from 0.1% to 14% and ecstasy use from 0.6% to 
13% in European countries (EMCDDA 2011a). Drug use is consistently more 
common among males than in females. 
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The use of drugs has grown during the past two decades in Estonia. In the 
total population of Estonia, aged 15 to 64 years, around 15% in 2003 and 21% 
of people in 2008 had tried an illicit drug at least once in their lifetime (Hansson 
2009). Six per cent of people aged 15 to 64 had used cannabis, 1% had used 
ecstasy and 1% amphetamines over the last 12 months. The use of heroin and 
synthetic heroin (analogues of fentanyl) has increased among general 
population. In general population survey in 2008 the total of 2% of participating 
males aged 15 to 24 had used heroin and 1% had used fentanyl in the last 12 
months, while in the same survey conducted in 2003, the use of heroin or 
fentanyl in the last 12 months was not reported (Hansson 2004; Hansson 2009).  
According to studies conducted by the European School Survey Project on 
Alcohol and Other Drugs (ESPAD) the proportion of adolescents aged 15–16 
years who had tried illicit drugs has increased through the years in Estonia. A 
total of 7% of adolescents had tried an illicit drug at least once in their lifetime 
in 1995, rising to 15% in 1999, 24% in 2003, 30% in 2007 and 32% in 2011 
(ESPAD Report 1995; ESPAD Report 1999; ESPAD Report 2003; ESPAD 
Report 2007; ESPAD Report 2011). Whilst in 1995 and 1999 the proportion of 
lifetime use of illicit drugs among Estonian schoolchildren was the lowest when 
compared with the average proportion of other European countries, since 2003 
the proportion has exceeded the European average (ESPAD Report 2011). 
Cannabis has been the most prevalent illicit drug amongst schoolchildren 
(lifetime prevalence in 2011 was 24%), followed by inhalants (16%) and non-
medical use of tranquillizers or sedatives (8%) among schoolchildren.  
The use of drugs is associated with opinions about those drugs. It is known 
that the beliefs concerning the harmfulness of drug use are inversely related to 
the prevalence of drug use (Compton et al., 2005). As drug use has become 
more prevalent in Estonia, it suggests that people`s corresponding beliefs about 
drugs have also changed. When using the results of ESPAD studies it can be 
seen that there has been decrease in the beliefs surrounding the dangers of 
cannabis use; over 60% of adolescents considered occasional cannabis use great 
risk during first ESPAD study in 1999, while less than half of respondents 
considered it as a great risk in 2011 (Figure 1). The less schoolchildren consider 
cannabis use or the use of other drugs a great risk, the more ready they are to try 
them. Data from a number of European countries show a high correlation 
between estimates of drug use in the adolescent population and adult population 
(Babor et al., 2010), so it can be assumed that beliefs about the dangers of drug 





Figure 1. Life-time use of cannabis among 15–16 year old adolescents in Estonia and 
perceived risk of occasional cannabis use in the ESPAD study, 1995–2011. 
 
 
2.1.4. Injecting drug use 
EMCDDA considers injecting drug use as being a “problem drug use” together 
with long duration or regular use of opioids, cocaine and/or amphetamines 
(EMCDDA 2009). The majority of problem drug use in Europe is formed by 
injecting drug use and the use of opioids, although in a few countries 
amphetamine use and often polydrug use are also prevalent (EMCDDA 2009).  
In most cases, drug users progress from mild drugs to stronger drugs and 
from non-injecting to injecting. The process is described by the “gateway 
effect”, according to which drug use is preceded by smoking and alcohol use, 
illicit drug use itself begins with cannabis smoking, and thereafter, progress is 
made to those drugs with a stronger effect (Kandel & Faust, 1975). Although 
there are doubts that the gateway effect in a strict sense does exist (Anthony 
2002; Morral et al., 2002a; Morral et al., 2002b). Variations in patterns of drug 
initiation suggest that entry into drug use is dependent on social factors, drug 
availability, characteristics of users and social settings that facilitate or deter use 
(Degenhardt et al., 2012). It has been found that the beginning of drug use is 
influenced more by social factors, both at the societal and individual level, 
while problem use is more associated with psychological factors (Frisher et al., 
2007).  
The risk factors for starting injecting may be socio-demographic or indi-
vidual, e.g. gender (more frequent among men) younger age, dropping out of 
school, smoking cannabis and crack, having an injecting sex partner, 
involvement of prostitution and contact with violence (Fuller et al., 2001; Fuller 
et al., 2002; Miller et al., 2006; Neaigus et al., 2001; Pates et al., 2005; Van 
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Ameijden et al., 1994; Van Ameijden & Coutinho 2001). Furthermore, transfer 
from non-injecting administration routes to injecting initiation may be more 
likely among some certain substance users, such as regular and long-term users 
of cocaine, heroin and tranquilisers (Van Ameijden et al., 1994, Van Ameijden 
& Coutinho 2001). Progress to injecting may be influenced by the desire to 
achieve a stronger effect and at the same time reduce costs (i.e. the same effect 
for less money) (Bravo et al., 2003). The reasons for not starting injecting have 
been mentioned as fear of blood and the injection process as well as fear of 
possible negative health outcomes, particularly HIV infection and overdose 
(Bravo et al., 2003). 
Previous research has documented that IDUs have increased risks associated 
with early onset of drug use (Anthony & Petronis 1995; Friedman et al., 1989; 
Fuller et al., 2001; Neaigus et al., 1996). It is known that younger IDUs are at a 
high level of risk for HIV and HCV, and engage in risky injection practices 
such as more frequent injecting, sharing syringes; sex-related risk behaviors like 
early sexual initiation, having unprotected sex, higher number of sexual partners 
and working at a young age in the sex trade (Becker Buxton et al., 2004; Des 
Jarlais et al., 1999; Fuller et al., 2001; Fuller et al., 2002; Kral et al., 2000; 
Miller et al., 2007). Understanding the relationship between early injecting 
initiation and possible consequences regarding later drug problems could help 
target prevention and early intervention. 
IDUs often combine drugs using multiple substances with different routes of 
administration, combined use (multiple substances, multiple administration 
routes) has being associated with particularly elevated risks (Southwell 2005). 
Different routes of administration of drugs carry different risks (Pates et al., 
2005). Drug users using non-injecting routes have lower risk of infections 
transmitted via blood, a lower risk of overdose and fewer problems with 
dependence syndrome. Also they will not suffer from the acute or chronic 
health conditions caused by injecting. There is evidence that while IDUs are at 
high risk of HIV through equipment sharing, the specific drugs injected (e.g. 
cocaine) may increase the risk of HIV infection, and that non-injecting drug use 
(particularly crack cocaine and methamphetamine) may increase the risk of 
sexual acquisition of HIV (DeBeck et al., 2009; Lloyd-Smith et al., 2009; 
Semple et al., 2010; Strathdee & Stockman 2010). Most research on HIV and 
drug use in Eastern Europe has focused on injecting without considering the 
potential impact of non-injecting drug use among injectors. There is limited 
data on the route of administration and on the nature of the harms to which drug 
users are exposing themselves (Strang et al., 1998).  
 
 
2.1.5. Injecting drug use in Estonia 
It has been estimated that almost 16 million (with a range of 11–21 million) 
people worldwide inject drugs (Mathers et al., 2008). The largest numbers of in-
jectors were found in China, the USA, and Russia, while over 40% of IDUs who 
are HIV positive are found in Estonia, Ukraine, Burma, Indonesia, Thailand, 
15 
Nepal, Argentina, Brazil, and Kenya (Mathers et al., 2008). Estonia has the 
highest estimated injecting drug use prevalence in Eastern Europe together with 
Russia, and the prevalence estimated in Western Europe is two to seven times 
lower compared with Estonia (Mathers et al., 2010). There are an estimated 
13,000 IDUs in Estonia with a prevalence of 2.4% of the adult population (aged 
15–44) (Uusküla et al., 2007a). Injecting drug use is most prevalent in the 
North-Eastern part of Estonia and in the capital, Tallinn. 
Since 2005, surveys have been carried out to study risk behaviour and the 
prevalence of infectious diseases among IDUs. These surveys have taken place 
in the Estonian cities of Tallinn (2005, 2007, 2009), Kohtla-Järve (2005, 2007), 
and Narva (2010) (Lõhmus et al., 2008; Lõhmus et al., 2011; Uusküla et al., 
2005; Uusküla et al., 2011). Based on the results it can be said that the majority 
of IDUs in Estonia are male, young adults (mean age 24 to 27 years) and ethnic 
Russian speakers, who represent about 85% of IDUs in Tallinn (the capital 
city), 98% in Kohtla-Järve and 76% in Narva (these latter two are cities near the 
Russian border) (Lõhmus et al., 2011; Uusküla et al., 2011). The average 
injection career has lengthened over the years, from six years (in 2005) to ten 
years (in 2009). The main drugs being injected have been fentanyl, produced in 
illegal drug labs, and amphetamine in Tallinn, poppy liquid in Kohtla-Järve, and 
amphetamines and fentanyl in Narva. The injection of fentanyl is associated 
with elevated injecting risk behaviour, fentanyl injectors have higher odds of 
being HIV positive and higher odds for lifetime overdose (Talu et al., 2010). 
Also polydrug use has been quite prevalent among IDUs throughout the years 
(Rüütel et al., 2011a). The estimated prevalence of HIV among injecting drug 
users is 40–90% and over 30% of IDUs have shared a syringe based on 
different studies (Platt et al., 2006; Uusküla et al., 2005; Uusküla et al., 2007b; 
Wilson et al., 2007).  
Injecting drug use is the main cause of HIV epidemic in Estonia, with the 
highest number of new HIV cases (31 cases per 100,000 people in 2009) in 
Europe and with the highest HIV prevalence among the adult population (1.2% 
in 2009) (ECDC 2011; UNAIDS 2011). Negative health consequences 
attributable to injecting drug use are the leading causes of death among males 
aged 25 to 30 year in Estonia (there were 27 HIV related deaths per 100,000 
males in 2009 and 104 deaths per 100,000 males caused by a drug overdose) 
(Statistics Estonia 2010). In addition to premature mortality among IDUs there 
are health related costs (e.g. the treatment of dependence disorder and infectious 
diseases – HIV, HCV), labour force loss (IDUs are young working-age males) 
and social costs (e.g. state benefits, criminal justice system and police arrests) to 
the society.  
The extent and severity of Estonian injecting drug use problem, affecting 
both IDUs and the wider community, reveals that there is a continuing need for 




2.2. Health and social services for drug users 
2.2.1. History and general concept of harm reduction 
Drug policy addresses both reducing the supply of drugs and reducing the 
demand, the latter encompassing prevention, treatment, rehabilitation and 
reducing the harms related to drug use. Defining what constitutes harm 
reduction has varied in the literature (Collins et al., 2012). In this thesis, the 
definition from the International Harm Reduction Association (IHRA) is used 
(IHRA 2010). The IHRA defines harm reduction as a perspective and a set of 
practical strategies to reduce the negative consequences of drug use, in-
corporating a spectrum of strategies from safer use to abstinence (IHRA 2010). 
The idea originates from a pragmatic approach that drug use has been present 
throughout history and some people will continue to engage in high-risk 
behaviors even though they experience associated harms. Ignoring or crimi-
nalizing drug use will lead to additional negative side-effects, and instead an 
appropriate drug policy with public health principles should be applied to 
minimize the related harms (Collins et al., 2012; Room & Reuter 2012). 
Another principle is a non-moralistic approach, drug abuse or dependence is 
seen more as an illness, often with relapses, not a criminal behavior, and 
services are delivered in a supportive and non-judgmental manner. Although the 
main aim is to minimize the consequences of drug use, harm reduction does not 
exclude or presume a dependence treatment goal of abstinence (Rhodes & 
Heidrich 2010).  
The spectrum of strategies refer to not only to specific interventions, but also 
to general principles on reforming drug policy and other public policies, 
through which societies respond to the drug problem (Hunt et al., 2003). Harm 
reduction principles can be used as a framework for all drugs including tobacco 
and alcohol use, but the focus of this thesis is on illegal drug use, especially on 
harms related to injecting drug use.  
One of the earliest forms of harm reduction dates back to the late 1950s, 
when the Canadian researcher Robert Halliday first practiced methadone 
treatment for opioid dependence (Hart 2007). Methadone maintenance was first 
introduced in 1964 in response to the outbreak of intravenous use of heroin in 
New York City (Courtwright et al., 1989). Contemporary ideas of harm 
reduction emerged in 1970s in the Netherlands, with a concern to integrate drug 
users into society and to maximize their contact with social, treatment, health 
and other community services (Lowinson et al., 2005). At the same time drug 
user organizations also appeared, so-called “Junkie Unions”, who distributed 
clean syringes at places were IDUs gathered, to reduce the spread of hepatitis 
(Grund et al., 1992). 
In the mid-1980s, to prevent the spread of HIV/AIDS, municipal syringe 
exchange programs were introduced at first in Netherlands and in Great Britain 
(O`Hare 2007). Although the particular concern was the risk of HIV infection, 
another concern was health risks associated with drug use and a poor lifestyle 
(Ashton & Seymour 2010; Seymour & Eaton 1997). People engaged with 
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injecting drug use were under served by health services and consumer led 
services for them were created for the first time in the UK in Liverpool and its 
surrounding area (Merseyside and Cheshire) (Seymour & Eaton 1997). The 
services aimed to give advice, primary care, clean injecting equipment, HIV 
testing and possibilities for opioid substitution therapy through drop in centers 
and outreach, in order to lessen the impact of injecting drug use on the health of 
affected individuals and the larger community. From this developed the Mersey 
Model of Harm Reduction which was soon adopted by Australia, Canada, 
Switzerland, and later by many other countries. The model is based on three 
principles: (1) it is important to make contact with whole population at risk; (2) 
maintain contact with the belief that as long there is contact with drug users, 
there is a possibility to influence to change their behavior; (3) make changes in 
their behavior (Ashton & Seymour 2010). 
 
 
2.2.2. Key services for HIV prevention and  
harm reduction for IDUs 
Preventing HIV transmission through injecting drug use is one of the key 
challenges and a comprehensive package for the prevention, treatment and care 
of HIV among IDUs is provided by WHO (WHO, UNODC, UNAIDS 2009). It 
includes (1) syringe exchange programs (SEPs); (2) opioid substitution therapy 
and other drug dependence treatment; (3) HIV testing with counseling; (4) 
antiretroviral therapy; (5) prevention and treatment of sexually transmitted 
diseases; (6) condom programs; (7) targeted information, education and 
communication for IDUs; (8) vaccination, diagnosis and treatment of HCV and 
(9) prevention, diagnosis and treatment of tuberculosis. 
 
1. Syringe exchange 
SEPs are associated with the harm reduction approach the most, and are perhaps 
the most widely available throughout the world. SEPs are reported to be 
available in all EU member states, in Australia, in parts of North America and 
within a number of developing and transitional countries (EMCDDA 2011a, 
Hunt et al., 2003). According to Mathers et al, SEPs were available in 82 
countries worldwide in 2009 (Mathers et al., 2010). At first it was argued that 
needle exchange may encourage injecting (Ashton & Seymour 2010; Grund et 
al., 1992). Now the evidence has proved the effectiveness of the SEPs in 
limiting the spread of HIV, HBV and HCV and other blood-borne diseases 
among IDUs (Bastos & Strathdee 2000; Des Jarlais et al., 1996; Palmateer et 
al., 2010). Also it has been documented that initiation and continuation of SEP 
use among high risk drug users is related to cessation of syringe sharing 
(Bluthenthal et al., 2000; Vazirian et al., 2005). 
There are different forms of SEPs – stand alone exchanges, based on 
community outreach workers, mobile services, SEPs attached to specialist drug 
services, pharmacy exchange services, accident and emergency departments, 
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genito-urinary clinics and primary care, depending on the country (Hunt et al., 
2003; Parsons  et al., 2002). Although a variety of possibilities are available, 
alternative modalities have been suggested to reduce HIV transmission, such as 
pharmacy sales, injector specific packs, mass distribution and vending machines 
(Coffin 2000; Obadia et al., 1999). Furthermore, studies conducted in Russia 
and Eastern Europe have stressed the need for additional sources of syringes 
besides SEPs in these high-risk areas (Aceijas et al., 2007; Sarang et al., 2008). 
But currently, data on pharmacists’ and IDUs’ attitudes and current practices 
relating to pharmacists’ role in harm reduction strategies are scant in Eastern 
Europe.  
The opportunity to exchange syringes in pharmacies has proved its 
effectiveness, and is most widely used in the United Kingdom, also in New Zea-
land, Australia and Ukraine (Lurie et al., 1998; Sheridan et al., 1996; Sheridan 
et al., 2005; Thein et al., 2003; USAID 2012). Complementary to offering 
sterile needles and syringes, other services such as the dispensing of injecting 
related paraphernalia (such as sterile wipes, “cookers”, filters and sterile water), 
methadone treatment and education regarding infection prevention and safer 
drug use have also been organized in pharmacies (Matheson et al., 2002; 
Sheridan et al., 1996, Sheridan et al., 2007; Strang et al., 1996). 
 
2. Opioid substitution therapy and other drug dependence treatment 
Opioid substitution therapy is available in all European countries, worldwide in 
a total of 70 countries and the provision of treatment has increased steeply 
through the last decade (EMCDDA 2011a; Mathers et al., 2010). Methadone is 
the most widely used and researched substitution medication, buprenorphine 
and the combination of buprenorphine/naloxone – Suboxone – are also 
commonly used (Gowing et al., 2011). It is estimated that overall about half of 
opioid users have access to treatment in Europe, comparable with those reported 
in Australia and the United States and higher than in Canada (EMCDDA 
2011a). While Russia has the highest number of opioid users, the drug addiction 
specialists strongly oppose to the use of substitution therapy (Mendelevich 
2011; Rechel 2010).  
The effectiveness of substitution treatment for opioid dependent drug users 
has been proved by a range of different studies, although the poor quality of 
provision reduces benefit (Bethesda 1995; Gowing et al., 2011; Strang et al., 
2012). It significantly reduces drug use, the injection of illegal drugs and the 
sharing of injecting equipment. In addition, less risky sexual behaviour and the 
reduction of crime and mortality have been observed. 
For a selected group of chronic heroin users heroin-assisted treatment is 
available in some countries (Netherlands, United Kingdom, Spain, Denmark, 
Germany, Switzerland, Canada) (EMCDDA 2011a; Hunt et al., 2003). This 
treatment is proposed for patients who have not responded to other treatment. 
Although the cost has been estimated between three to 10 times higher than 
methadone treatment, it has shown to be cost-effective (EMCDDA 2011b). 
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The harm-reduction principle, aimed to achieve contact with drug users and 
services delivered in a non-judgmental manner, is focused on achieving a 
change in the drug user`s behavior. Therefore individual and group-level 
approaches are central components for promoting health behavior change. 
Counseling intervention with motivational interviewing, in combination with 
case management, is considered effective in treating drug dependence (Hunt et 
al., 2003; Lundahl et al., 2010; Robles et al., 2004). In addition, other psycho-
social interventions are used including cognitive behavioral therapy, contin-
gency management, community reinforcement approach, matrix model, 
therapeutic community model, the Minnesota model and the12-step recovery 
approach (e.g. Narcotics Anonymous) (Board on Global Health 2006).  
 
3. Other services for IDUs 
Naloxone, an opioid antagonist, is a medication which counters the effects of an 
opioid overdose and has been used by emergency staff in many countries, but is 
now becoming more widely distributed by harm reduction services to people 
who use drugs, their peers and families. The provision of naloxone with training 
of users and families to prevent opioid overdose deaths has been introduced in 
several countries in the United Kingdom, Germany, Italy, the United States, 
Canada (Baca & Grant 2005; Sporer & Kral 2007). 
Drug consumption rooms have proved to reduce harms related to drug use, 
like prevention of HIV, HCV and HBV, reducing overdoses to prevent deaths, 
facilitating access to treatment and other health and social services, reducing 
street drug use and associated litter (Hunt et al., 2006; Lloyd & Godfrey 2010). 
Also they are effective modalities for attracting more marginalized and 
vulnerable drug users. Drug consumption rooms are available in Germany, 
Switzerland, the Netherlands, Spain, Norway, Luxembourg, Australia, Canada 
(Hunt et al., 2006). 
WHO describes information, education and communication approaches 
essential to reduce the risks and harms related to drug use (Hunt et al., 2003). 
Distributing leaflets on advertising services, information on reducing risk-
taking, management of medical crises such as overdose, are widely used to 
complement other services. 
Illicit drug markets are attributed to the harms related to drug use due to poor 
product quality and harm-reduction responses include early warning systems 
and pill testing (Hunt et al., 2003). Early warning systems have been developed 
to monitor changes in drug consumption patterns and monitor the appearance of 
new substances (EMCDDA 2007). Pill testing is an option for drug users to test 
their pills, used most frequently ecstasy-like substances, to get information 
about the quality of the substance and this also allows the monitoring of the 
drug market and alerting early warning systems about the strength/purity or 
contamination of drugs (EMCDDA 2001). This development is a part of Dutch 
drug policy and is to some extent used in Austria, Belgium, France, Germany, 
Spain and Switzerland. 
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4. Efectiveness of harm reduction interventions 
As noted above, harm reduction is a package of different strategies and 
evidence implies that harm reduction services have an enhanced impact when 
they are used in combination (Collins et al., 2012; Rhodes & Hedrich 2010). 
Syringe exchange in combination with substitution treatment is more effective 
in reducing HIV and HCV risk than stand-alone interventions (Van den Berg et 
al., 2007). Additionally, syringe exchange in combination with HIV-testing, 
counseling for infectious diseases and information and education materials 
helps to limit the spread of infectious diseases among drug users (Arponen et 
al., 2008). A similarly enhanced effect has resulted from the combination of 
substitution treatment and adherence to AIDS treatment or integrating AIDS 
treatment with tuberculosis treatment (Rhodes & Hedrich 2010). 
A recent meta review of existing studies and data documented evidence in 
support of a variety of harm reduction interventions (Kimber et al., 2010). A 



















HIV transmission Sufficient evidence 
that OST reduces 
HIV transmission 
Tentative evidence 
that SEP reduces 
HIV transmission 
Insufficient 
evidence that PND 
reduces HIV 
transmission 
Hepatitis C (HVC) 
transmission 
Tentative evidence 

















that OST reduces 
risk behaviors 
Sufficient evidence 
that SEP reduces 
risk behaviors 
Sufficient evidence 





that OST reduces 
overdose mortality 
Insufficient evidence 
about effect on 
overdose deaths 
 





2.2.3. Services for HIV prevention and  
harm reduction for IDUs in Estonia 
The main services for IDUs in Estonia are the SEPs and the opioid substitution 
therapy with methadone, provided by non-profit organizations and mainly 
funded by the state according to the national HIV/AIDS strategy (Laisaar et al., 
2011). 
SEPs were initiated in Estonia in 1997, in Tallinn. By 2010 nine non-
governmental organizations were providing syringe exchange and counseling 
services in 36 syringe exchange points, 13 of which were stationary centers, 
located in high drug use areas in Tallinn and in the North-Eastern part of 
Estonia (EUSK 2011). There were approximately 7,000 customers and more 
than 2.1 million syringes were distributed in 2011. When using estimations of 
IDU prevalence, it can be said that roughly about 60% of IDUs are covered by 
syringe exchange services in Estonia. In the presence of a high prevalence of 
injecting drug use and HIV, there is a need for complementary approaches to 
increase the availability of clean syringes for IDUs in Estonia. For harm 
reduction policy and practical solutions, evidence-based data is needed on 
involving pharmacies in harm reduction, and potential barriers. 
While methadone detoxification has been present in Estonia since 1998, 
opioid substitution treatment with methadone was officially introduced in 2001, 
although it has only become used on a significant scale since 2003 with the 
opening of a specialized centers (Abel-Ollo et al., 2008; Laisaar et al., 2011). 
There were six substitution treatment providers in eight different settings in 
2011 in Estonia and a total of 1,064 clients received methadone substitution 
treatment in 2010. However the proportion of drug users treated remains low, it 
is estimated that approximately 7% is covered by treatment (Mathers et al., 
2010). Buprenorphine has been available since 2003, but is not widely used, 
probably due to the fact that clients are supposed to pay themselves (Laisaar et 
al., 2011). Assessment on the quality of methadone substitution treatment in 
Estonia claimed that for effective treatment in addition to dispensing of 
methadone, behavioural and psychological interventions should be integrated 
more thoroughly (Abel-Ollo et al., 2008).  
Free voluntary HIV-testing and counseling services were provided in the 
eight AIDS counseling centers in 2010, and for the population groups at the 
most risk via prevention and harm reduction services voluntary HIV-testing is 
available in Estonia (EUSK 2011; Laisaar et al., 2011). Furthermore the 
provision of free and anonymous diagnostics and treatment services for sexually 
transmitted infections targeted IDUs and their sexual partners is available in 
Jõhvi and Narva, cities in North-Eastern part of Estonia. Studies have shown 
that about 2% of IDUs have been diagnosed with tuberculosis and there is need 
for services to refer IDUs to tuberculosis screening (Rüütel et al., 2011a; Rüütel 
et al., 2011b). More than half (55%) of all persons with tuberculosis and HIV 
dual infection in Estonia were drug users in 2010 (Viiklepp, personal 
communication, 2011).  
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This thesis concentrates on problems related to injecting drug use, as it 
represents a significant and important public health issue in Estonia. Despite the 
efforts injecting drug use is a major contributor to preventable morbidity and 
mortality, associated with harms and costs due to high number of acquired 
blood-borne infections (HIV, HCV, HBV), high number of overdoses and crime 
among youth and young adult populations. There is need to respond more 




2.3. Drug use research and drug policy 
While the use of drugs dates back throughout history, modern drug policy is 
over a century old and reflects how societies deal with the problems caused by 
drugs through laws and programs (Babor et al., 2010). There are a multitude of 
approaches aimed at tackling the challenges of illicit drugs and targeting 
different dimensions of problems relating to drugs. These different approaches 
can target and impact on different aspects of society, such as health, safety and 
public order, the criminal justice system and social and economic functioning. 
Policies can be devised in terms of the harms they seek to minimise, the sources 
they seek to affect, or those who bear the burden of the encountered harms 
(MacCon & Reuter, 2001). 
National and international approaches to tackling the challenges of illicit 
drugs tend to be mixed (Culley et al., 2012). Firstly, governments and inter-
national organisations deploy a range of measures aimed at targeting the supply 
of illicit drugs, through law enforcement interventions, seizures, precursor 
interdictions, and destruction of production facilities and crops. Secondly, there 
are measures that are intended to reduce the demand for illicit drugs, by 
targeting users or potential users directly; these include education and 
information provision through a variety of different media, early interventions 
with at risk groups, treatment and possession bans. Finally, there are inter-
ventions geared at reducing harms such as illnesses and morbidity, for example 
through needle exchange programs or substitution treatment. 
Drugs policy at the European Union (EU) level is coordinated by the 
European Commission and it functions as the main executive body and is 
responsible for EU level actions (Culley et al., 2012). The main EU technical 
and operational agencies in the drugs field are the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA), Europol (the European Police 
Office) and Eurojust (the European agency for judicial cooperation).  
The EMCDDA is a reference point, gathering data and publishing reports on 
the drugs situation in the EU (EMCDDA 2012). It coordinates the European 
Information Network on Drugs and Drug Addiction (REITOX) for the 
collection and exchange of data and information on drugs and drug addiction 
between 27 Member States of the EU, Norway, Turkey, Croatia and the 
European Commission. 
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Europol plays an important role in terms of law enforcement coordination 
and expertise. It facilitates and supports cross-border investigations and 
operations, provides information on drug trafficking, and acts as a central 
institute from which the Member States of the EU can draw expertise 
(EUROPOL 2012). Europol also publishes reports that are disseminated to the 
EU policymakers and the law enforcement community in the Member States. 
Eurojust is the body that improves the coordination of investigations and 
prosecutions between competent authorities in the Member States of the EU and 
contact points in 24 non-Member States (Eurojust 2012). 
Internationally, the United Nations Office on Drugs and Crime (UNODC) 
plays a key role in coordinating action and assisting member nations in 
addressing the challenges associated with illicit drugs, drawing on key legal 
instruments that form the basis of international cooperation in the field 
(UNODC 2012). The Commission on Narcotic Drugs is the main body dealing 
with this area in the United Nations system. 
The EU Drugs Strategy and Action Plans employ a combination of 
approaches to tackling drugs. The Strategy has two policy areas – supply 
reduction and demand reduction – and three cross-cutting themes – coordi-
nation, international cooperation, and information, research and evaluation 
(Culley et al., 2012). An important aspect of EU drugs policy has been the 
creation of an evidence base through the development of new indicators and 
systematic collection of data on drugs in the EU. In Europe national drug 
strategies are designed at the national level and the EU Drugs Strategy is 
expected to add value to national-level drugs policy. According to EMCDDA 
every Member State of the EU has a national drug strategy supported by an 
action plan with concrete targets and time line (EMCDDA 2010). 
In Estonia drug-related research and drug policy is regulated by the National 
Strategy on the Prevention on Drug Dependency 2004–2012 (NSPDD) and the 
National Strategy for the Prevention of HIV/AIDS 2006–2015. NSPDD came 
into force in 2005, before that drug policy was regulated by Alcohol and Drug 
Abuse Strategy since 1997. The field of harm reduction (i.e. syringe exchanges, 
methadone substitution treatment, and distributing condoms) is regulated by the 
National HIV/AIDS Prevention Strategy, which is the fourth national program. 
The first National AIDS Prevention Program was approved in effect in 1992–
1996, the second program, the National Action Plan for Prevention of 
HIV/AIDS and other Sexually Transmitted Diseases was implemented in 1997–
2001, and the third was adopted in 2002–2006. The Ministry of Social Affairs is 
the main coordinator involving the Ministry of Education and Research, the 
Ministry of Internal Affairs, the Ministry of Justice, the Ministry of Finances 
and other partners. According to the recent plans after the end of NSPDD in 
2012 and the National HIV/AIDS Prevention Strategy in 2015, drug policy with 
HIV/AIDS prevention strategy will fall under the Estonian National Health 
Strategy and there will be no separate strategies coordinating the drug field 
solely. 
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3. AIMS OF THE RESEARCH 
 
The general aim of this research was to evaluate drug use and risk behaviour 
among people who inject drugs (IDUs), their use of harm reduction services 
targeting them and the introduction of possible new harm reduction services, in 
Estonia. 
 
The specific aims were: 
1. To describe the initiation of drug use and to explore possible consequences 
of early initiation into injecting drug use on further risk behavior and on HIV 
prevalence (Paper I);  
2. To examine the relationship between routes of drug administration and HIV 
serostatus and to identify related socio-demographic, drug-use related factors 
and sexual risk behaviours among IDUs (Paper II); 
3. To determine the occurrence of risk behaviour and HIV infection prevalence, 
coverage with and use of harm reduction services by the IDUs who primarily 
use syringe exchange programmes (SEPs) compared with those who 
primarily use pharmacies as their source of sterile syringes in Tallinn (Paper 
III);   
4. To explore pharmacists’ and IDUs’ attitudes toward the role of pharmacists 
in HIV prevention activities for IDUs and discover potential barriers that 
might prevent the sale of syringes from pharmacies and regarding the 





4. MATERIALS AND METHODS 
 
The current work is based on the results of two cross-sectional studies and on 
two qualitative studies. 
 
 
4.1. Cross-sectional studies 
4.1.1. Study design, setting, and interventions 
Cross-sectional studies using respondent-driven sampling (RDS) (Uusküla et al 
2011) were used to recruit IDUs for interviewer-administered surveys in 2007 
(Paper I; Paper II; Paper III) and in 2009 (Paper I) in Tallinn, Estonia. Inclusion 
criteria in both studies were being 18 years or older, either a Russian or 
Estonian language speaker, having had injected in the previous two months and 
being able to provide informed consent. Recruitment began with the non-
random selection of five to six ‘seeds’ representing diverse IDU types (by 
gender, ethnicity, main type of drug used, engaging in sex for money and HIV 
serostatus). Eligible participants were provided with coupons for recruiting up 
to three of their peers. Coupons were uniquely coded to link participants to their 
survey responses and biological specimens and for monitoring who recruited 
whom. Participants who completed the study received a primary incentive (a 
food voucher worth 6.40 Euros) for participation in the study and a secondary 
incentive (food vouchers worth 3.20 Euros for each eligible person they 
recruited to the study). The RDS technique uses participants’ social networks to 
access individuals who may not appear in public venues and are not in contact 
with service providers (Heckathorn 1997; Heckathorn 2002; Heckathorn et al., 
2002; Salganik & Heckathorn 2004). 
An interviewer-administered questionnaire in face-to-face interviews was 
used in both studies in 2007 and in 2009 (Paper I; Paper II; Paper III), based on 
the WHO Drug Injecting Study Phase II survey (version 2b (rev.2)) (Des Jarlais 
et al., 2006). Interviews were held in confidence, in a room of the syringe 
exchange program (SEP) between the IDU participant and the interviewer. 
Recruitments were conducted and the surveys administrated by a team of 
trained fieldworkers. The study protocols included pre- and post-HIV test 
counseling for study participants.  
Venous blood was collected from participants and tested with commercially 
available kits for HIV antibodies Vironostika HIV Uniform II Ag/Ab 
(BioMerieux); positive cases were confirmed with INNO LIA HIV I/II Score 
Westernblot in 2007 and using Abbott IMx HIV-1/HIV-2 III Plus (Abbott 
Laboratories) in 2009. The testing was conducted at the state HIV/AIDS 




4.1.2. Statistical analysis 
For data analysis primary descriptive variables included age of onset of 
injecting drug use, substances used, frequency and patterns of injecting drug 
use, risk behavior including sexual risk behavior, utilization of harm reduction 
services and HIV serostatus. Correlates with selected outcome measures (see 
below) were explored using the chi-square test for proportions, Fisher’s exact 
test for small cell expected values (<5), the t-test for normally distributed 
continuous variables, the Wilcoxon rank sum test for non-normally distributed 
continuous variables and ordered categories together with multiple logistic 
regression analysis to assess confounding and interaction between variables. 
Odds ratios (OR) and adjusted odds ratios (AOR) are reported together with the 
95% confidence intervals (CI). 
 
Main outcome measures:  
 For analysis in Paper I, the main outcome measure was age at IDU 
initiation. IDUs were categorized into two groups, ”early initiators” 
who reported starting injecting drug use at 15 years or younger and 
”later initiators” starting injecting at 16 years or older. At first, analysis 
was carried out separately in the samples of 2007 and 2009, to check if 
there were differences between the samples; factors used in the analysis 
did not differ between the study years and therefore in the analysis, 
presented data from 2007 and 2009 were combined to increase the 
power of the analysis. AORs were calculated using length of injecting 
career and study year as control variables in a logistic regression model. 
To assess the association between HIV serostatus and early injecting 
initiation, logistic regression analysis was used with serostatus as an 
outcome measure and control for the effect of variables representing 
characteristics and events associated with beginning to inject that would 
have likely occurred before HIV infection and duration of injecting. 
 In Paper II the mode of drug use administration (exclusive IDU, non-
exclusive IDU) was selected for main outcome measure; subjects were 
classified into exclusive injectors (who reported only injecting drug use 
in the six months prior to the interview) or non-exclusive injectors (who 
reported injecting plus other routes of drug administration in the six 
months prior to the interview). Using multiple routes was defined as 
injecting during the last six months plus at least monthly use of at least 
one illicit drug other than by injection. Marijuana use was included as 
non-injecting drug use, but alcohol use and cigarette smoking were not. 
HIV serostatus, risk behaviors and characteristics were compared 
between the two groups. AORs were calculated using a logistic 
regression model, adjusted for gender, age, employment status, age at 
IDU initiation, years injecting and frequency of injecting per day. 
 In Paper III, the primary source for clean syringes was selected for an 
outcome; respondents were categorized into two groups, pharmacy or 
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SEP (which included IDUs who got their syringes from SEP outreach 
workers) based on their self-reported main source for clean syringes 
within the previous six months. Multivariate analysis was conducted to 
explore factors associated with using pharmacies as a main source of 
syringes. AORs were calculated using gender, age, employment status, 
duration of injection career and frequency of injecting per day as 
control variables in a logistic regression model. 
 
Statistical analyses were carried out using Stata 9 for Windows software (Stata 
2005). RDS analysis Tool v. 5.0.1 was used to calculate homophily to examine 
for possible recruitment bias (Volz et al., 2007). 
Ethical approval was obtained from the Tallinn Medical Research Ethics 
Committee (in 2007) and from the University of Tartu, Estonia (in 2009). 
 
 
4.2. Formative research 
Qualitative research is recommended during early phases of intervention 
development, and is used to gain insight into people's attitudes, behaviours, 
value systems or lifestyles (Mack et al., 2005; Morgan 1988). Focus groups can 
help to determine a broad range of views on a specific topic, and the 
opportunity for group interaction stimulates conversation and reactions. To 
inform the research, interpretation and decision making focus groups both with 
target group members (IDUs) and service providers (pharmacists) were 
conducted. 
For Paper II, qualitative research including focus groups with IDUs were 
conducted. A total of 16 IDUs took part in four focus groups held between 
December 2009 and January 2010 in Tallinn. Focus group participants were 
recruited via a drop-in center and SEPs. The groups were run by trained 
moderators using a semi-structured guide. The focus group discussions were 
audio recorded with participants’ consent, and recordings were transcribed. 
Sources of qualitative data included notes, summaries, and transcriptions. 
Content and themes emerging from the qualitative data were analyzed by 
project staff to guide the analysis and interpretation of the survey findings. 
Information was gathered to determine: (1) why some IDUs are exclusive 
injectors and some prefer multiple routes of administration; (2) which drugs are 
administered; (3) all possible routes of administration. Sexual behavior was not 
addressed in the focus groups. Informed consent was obtained from the 
participants. Focus groups were held in Russian, as the majority of IDUs are 
Russian speakers, and were translated into Estonian for analysis. 
Paper IV based on the focus groups with pharmacists and IDUs. A total of 
140 pharmacies were identified in Tallinn and a random sample of 70 
pharmacies was selected. Pharmacists from the selected pharmacies were 
invited to participate in focus groups through telephone contact with one of the 
researchers. Respondents were offered gift cards worth 300 Estonian Kroons 
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(around 19 Euros) for their time and contribution to the study. Discussions 
focused on: (1) background attitudes and beliefs about HIV/AIDS, IDUs and 
SEPs; (2) syringe sale practices and attitudes to selling syringes to IDUs; (3) 
involvement of pharmacies in HIV prevention and their willingness to 
cooperate. 
IDUs were recruited via a drop-in center which provides services for IDUs 
from all over Tallinn and which has previous experience in accessing IDU 
networks. IDU respondents were offered gift cards worth 100 Estonian kroons 
(around 6 Euros) for their time and contribution to the study. Discussions 
focused on: (1) possible sources for clean syringes and attitudes toward SEPs; 
(2) experiences of syringe sale practices in pharmacies; (3) suggestions about 
involving pharmacies in HIV prevention. 
There were six focus groups with pharmacists and IDUs, held from January 
to May 2008 in Tallinn. Three focus groups were with pharmacists, where a 
total of 19 participants took part. In three focus groups with IDUs, a total of 15 
individuals participated. 
Focus groups generally lasted one hour and were conducted in Estonian or 
Russian depending on the language preferred by the participants. Informed 
consent was obtained from the participants. A semi-structured guide was used 
for conducting the focus groups. All interviews were audio-taped and 
transcribed. Focus groups held in Russian were translated into Estonian for 
analysis. Data from the transcripts was first coded according to the main study 
questions. After a second reading, the researcher formulated subcategories for 
each main theme. After a third reading, the researcher selected subcategories 
depending on how frequently they appeared in the transcripts. Initial coding was 
done by one researcher, after that second researcher read through the initial 
coding, where coding disagreements were identified the topic was recorded 
based on discussion between the researchers. Both researchers were present in 
all focus groups. The specific quotes reported in the results were chosen to 
reflect common attitudes.  
Analyses were carried out using NVivo 8 software (NVivo 2008). 




5. RESULTS AND DISCUSSION 
5.1. Characteristics of participants 
IDUs who participated in the studies in 2007 and 2009 in Tallinn were mainly 
Russian-speaking males with mean age of 27 years. Over 70% had been 
injecting for more than five years, the primary drugs injected were fenatnyl and 
amphetamine. The frequent use of fentanyl is the cause of high number of 
overdoses, more than 60% of respondents had experienced a non-fatal overdose. 
About third of IDUs had shared syringes during last six months and more than 
half of them were HIV seropositive. Main characteristics of study participants 
are described in the Table 2. 
 
 
Table 2. Main characteristics of IDUs in Tallinn, in 2007 and in 2009 studies 
 2007  2009  
 n % 95%CI n % 95%CI 
Age (mean; SD) (26.5; 5.7) 26–27 (27.7; 5.5) 27–28 
Gender:    
Male 294 84 80–88 272 82 78–86 
Female 56 16 12–20 59 18 14–22 
Ethnicity:   
Russian/Russian speaking 286 85 81–89 282 93 90–96 
Estonian 51 15 11–19 20 7 4–10 
Educational level (years):    
10–12  155 45 40–51 168 51 45–56 
≤9  186 55 49–60 163 49 44–55 
Main source of income in last 6 months:    
Regular or temporary  job 187 53 48–59 112 34 29–39 
Other* 163 47 41–52 219 66 61–71 
Having health insurance:    
No  196 57 51–62 179 54 49–60 
Yes 150 43 38–49 151 46 40–51 
Drug use initiation:   
By other means of    
administration 
238 68 63–73 198 60 54–65 
Injecting 112 32 27–37 133 40 35–46 
Duration of injecting career:   
0–2 years 40 11 8–15 23 7 4–10 
3–5 years 65 19 15–23 46 14 10–18 
6–10 years 156 45 40–50 119 36 31–41 
≥11 years 87 25 21–30 143 43 38–49 
Frequency of injecting 
during last 4 weeks: 
  
Less than daily 109 31 26–36 205 63 57–68 
Daily 241 69 64–74 122 37 32–43 
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 2007  2009  
 n % 95%CI n % 95%CI 
Main drug injected during last 4 weeks: 
Fentanyl 249 72 67–77 169 55 49–61 
Amphetamine 90 26 22–31 85 28 23–33 
Other 5 2 0.5–3 52 17 13–22 
Ever overdosed:   
No 128 37 32–42 107 32 27–38 
Yes 222 63 58–68 224 68 62–73 
Sharing syringes during last 6 months: 
No 223 64 59–69 227 70 64–75 
Yes 124 36 31–41 96 30 25–35 
HIV serostatus:   
Negative 157 45 40–50 164 50 44–55 
Positive 193 55 50–60 167 50 45–56 
Ever had HIV test:   
No 52 15 11–19 44 13 10–17 
Yes 297 85 81–89 286 87 83–90 
Ever received drug-related  treatment:  
No  214 61 56–66 179 54 49–60 
Yes 136 39 34–44 152 46 40–51 
Ever been in prison:    
No  146 42 36–47 136 41 36–47 
Yes 204 58 53–64 195 59 53–64 
* “Other“ means goverment benefits, spouse, partner, relative or friend`s income, street 




5.2. Initiation of drug use and possible consequences  
of early initiation into injecting drug use (Paper I) 
The mean age of starting to inject drugs in the 672 current IDUs included in the 
study was 18 years with a range of 9 to 42 years. Almost a quarter (23%; 
n=156) reported early initiation (i.e at or below 15 years of age). The numbers 
of early and later initiators by calendar year are presented in Figure 2. Some 
similarities can be observed in the curves for those with very young age and 
those with older age at first injection. Namely the rapid rise in the mid and late 
1990s and highest numbers of IDU initiators in the years 1996 to 2000. Since 
the 2000s, the number of early initiators declined steeply while the numbers of 
later initiators remained relatively unchanged. A steady increase in the number 
of early injectors from the 1990s until 2000 coincides with the period of 
transition when Estonia faced major socio-political and economic changes after 
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Figure 2. Number of late- and early-injecting initiators beginning injecting by calendar 
year.   
 
 
IDUs initiating injection early differed significantly from their older initiate 
counterparts, namely by exhibiting higher risk behaviour both at the time of 
initiation and later in their IDU-career. According to 2009 study (there were no 
tobacco and alcohol use questions in 2007 study questionnaire) early initiators 
were younger as regards their first tobacco use (the mean age 10.3 vs 12.7 
years, p<0.001) and their first alcohol use (the mean age 12.3 vs 14.2 years). 
Being younger at first use of either tobacco (r=0.4, p<0.001) or alcohol (r=0.4, 
p<0.001) was positively correlated to first use of illicit drugs. Overall smoking 
prevalence among IDUs was 99% and 51% reported alcohol use at least once a 
week; there were no differences between early versus later initiators.  
Early initiators had a three times shorter interval between initiation of illicit 
drug use to escalation into injecting drugs (mean of 0.5 vs 1.6 years, p<0.001). 
In the long term, early initiation was associated with socio-demographic factors 
(e.g. lower educational level, being currently unemployed) and high risk 
injection behaviour (e.g. higher intensity of sharing syringes and paraphernalia) 
(Table 2 in Paper I). The early initiators also had significantly higher HIV 
seropositivity (AOR 2.12; 95%CI 1.45–3.12). These findings suggest some 
important implications for the development of interventions. 
There are implications for health educators who are developing and 
implementing prevention programs. A recent study among Estonian teachers 
revealed that teachers were uncertain in what form and to what extent specific 
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subjects regarding drug education should be addressed and exaggerating the 
dangers of drug use were considered effective (Vorobjov et al., 2011). ESPAD 
surveys results – higher proportion of lifetime use of illicit drugs (including 
cannabis) in Estonia than European average proportion – supports the evidence 
that drug education stressing the dangers of drug use do not have effect on the 
youth`s behavior (Faggiano et al., 2008). Instead, drug prevention programs for 
youth should provide accurate information with teaching resistance skills using 
social influence approaches and normative education (Babor et al., 2010). Due 
to the strength of the associations between several variables associated with 
early age of onset of substance use and other health risk behaviours among 
middle school students, comprehensive prevention programs should be initiated 
during elementary school and continued at least through middle school (Du 
Rant et al., 1999, Kokkevi et al., 2006). In addition, programs which provide 
alternative activities, such as family and/or community based interventions or 
mass-media campaigns, can be helpful, although there is little evidence of their 
effect (Babor et al., 2010). 
There are implications for public health professionals and for primary health 
care providers. For example, there should not be any age restrictions on access 
to harm reduction services such as syringe exchange and substitution therapy 
(EHRN 2009). In addition it is common that children with substance abuse 
problems are often co-morbid with anxiety, depression, attention deficit 
hyperactivity disorder, or some other psychiatric disorder (Deas 2006; Shrier et 
al., 2003). Psychiatric disorder when neglected in childhood may lead to 
adolescent illicit drug use, therefore screening for substance use is important 
even in young adolescence. Interventions should not only focus on helping 
patients discontinue their drug use, but also address those factors in children’s 
lives that are associated with the drug use, which may require the help of mental 
health care professionals (Du Rant et al., 1999; McLellan & Meyers 2004; 
Winters 1999).  
There appeared multiple adverse health consequences – HIV infection in 
particular – associated with early initiation into drug injecting in Estonia that 
emphasize the need for early intervention efforts targeting young people at risk 
of early initiation into drug injecting and policies aimed at delaying the age of 
starting drug use, including injecting drug use, which may contribute to 
reducing risk behaviour among IDUs. 
 
 
5.3. Routes of drug administration, related risk factors and 
HIV serostatus among IDUs (Paper II) 
Across the sample of 350 current IDUs, there was a small, but significant subset 
of IDUs (14%, n=49) who, besides injecting, administered drugs also by other 
routes. These IDUs who also used other routes were less likely to be HIV 
seropositive (AOR 0.49; 95%CI 0.25–0.97) and reported lower frequency of 
injecting (proportions of daily injectors 47% vs 72%, p=0.001). Our findings 
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were similar to the study among IDUs in New York City (Des Jarlais et al., 
2011): injectors who reported intranasal heroin use in addition to injecting drugs 
were significantly less likely to be HCV seropositive than those who did not 
report intranasal heroin use (AOR 0.52; 95% CI 0.33–0.82). Thus, it may be 
suggested that substituting non-injecting drug use for injecting drug use may be 
having a protective effect against infection with blood-borne viruses among 
those who are not infected yet.  
Those reporting other routes exhibited more risky sexual behavior. Namely, 
IDUs reporting multiple routes of drug administration were more likely to 
report multiple sexual partners in the previous 12 months (59% vs 43%, 
p=0.033) and a higher number of self-reported sexually transmitted diseases 
(20% vs 9%, p=0.019). Although non-exclusive IDUs had a lower HIV 
prevalence than exclusive injectors (35% vs 59%, p=0.002) the HIV prevalence 
was substantially high and warrants attention and measures to prevent the 
heterosexual transmission of HIV into the general population and raises the 
need for tailored harm-reduction services. Possible interventions for non-
exclusive IDUs exhibiting high sexual risk behavior might include HIV testing 
with counseling; STI testing and treatment, and, in the light of recent studies, 
timely initiation of HAART, if infected, may further help to reduce sexual 
transmission of HIV (Cohen et al., 2011). 
Although there were no differences between the exclusive injectors and 
injectors reporting multiple routes of administration in terms of the frequency of 
overdoses, a high overall rate of self-reported non-fatal overdoses (over 60%) 
requires attention. During the focus group interviews some IDUs reported that 
they try new drugs by other routes before injecting or start by injecting small 
amounts for precautionary reasons, when the strength or purity of the drug was 
not trusted. Nevertheless there is need for overdose prevention training among 
IDUs perhaps including greater access to naloxone (Green et al., 2008). At 
present, naloxone is available only in emergency care and there are no overdose 
prevention programs in Estonia. 
The relevant message from this paper is that HIV prevention programs for IDUs 
need to address non-injection as well as injection drug-use. The substitution of non-
injecting drug use for injecting drug use may be a potentially important new method 
for reducing HIV through sharing of injecting equipment. In addition to promoting 
alternatives to injecting, interventions might incorporate social marketing 
campaigns to reinforce the positive identity of non-injectors, non-injecting 
treatment options to encourage reverse transition or short-term prescribing to 
lower the tolerance (Southwell 2005). 
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5.4. HIV infection and risk behavior prevalence and 
utilization of harm reduction services by IDUs (Paper III) 
Three hundred and fifty IDUs completed the questionnaire. A total of 99% 
answered that they had received new and unused syringes during the previous 
six months. The sources for new and unused syringes in that six month period 
were: pharmacies, 80%; SEPs, 72%; SEP outreach workers, 37%; friends, 23%; 
other drug users, 6%; drug workers and drug agencies, 4%; sexual partners, 2%; 
and street vendors, 1% (multiple responses allowed). Over 80% have had HIV 
testing prior to the study and about 40% reported having drug abuse treatment. 
In a context of high HIV incidence and prevalence among IDUs, this paper 
investigated if there are differences between the individuals who primarily use 
SEPs compared with those who primarily use pharmacies as their source of 
sterile syringes in Tallinn and whether pharmacies could complement SEPs in 
dispensing syringes and other injecting equipment.  
IDUs using mainly pharmacies were at a less “advanced” stage of their 
injection career. Pharmacy user group included a higher proportion of new in-
jectors (those reporting injecting two years or less) (16% vs 6%, p=0.002). Also 
they reported lower injection frequencies: less likely to inject daily (62% vs 
76%, p=0.009) and lower injecting frequency on the last day they injected 
(proportion of users reporting more than one injection per day 75% vs 89%, 
p=0.002), and fewer fentanyl users among pharmacy users (74% vs 85%, 
p=0.015). 
New injectors create special problems for HIV prevention, they may increase 
the size of the local IDU population with increasing the need for prevention and 
treatment services. In addition they may not self identify as IDUs and may not 
fully appreciate the need to protect themselves against HIV and other blood-
borne diseases, and may find HIV prevention and drug services difficult to 
access. Therefore pharmacies could be a key role in connecting IDUs to treat-
ment and preventive services prior to a transition to riskier to riskier use of 
injection drugs. There are several examples in Europe, Australia, New Zealand, 
the United States, and also in Ukraine where pharmacies have been involved in 
providing services for drug users (Deren et al., 2003; Lurie et al., 1998; 
Matheson et al., 2002; Thein et al., 2003; USAID 2012). Despite some concerns 
for safety and about improperly discarded syringes, as well as undesired effects 
that drug users might have on the sensitivities of other business customers 
(Fuller et al., 2004; Lewis et al., 2002; Lurie et al., 1998; Taussig et al., 2002) it 
has been feasible to recruit pharmacists to provide services to IDUs (Matheson 
et al., 1999; Sheridan et al., 1997; USAID 2012) and to cultivate a public health 
perspective among pharmacists (Coffin et al., 2000; Rich et al., 2002; Taussig et 
al., 2002; USAID 2012). 
As HIV and HCV prevalence were high in both groups the pharmacy group 
had somewhat lower odds for being infected with either HIV or HCV (AOR 
0.54; 95%CI 0.33–0.87 and AOR 0.10; 95%CI 0.02–0.50, accordingly). But 
pharmacy users had close to two times higher odds of reporting multiple sexual 
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partners (AOR 1.88; 95%CI 1.17–3.04) and casual sexual partners (AOR 2.09; 
95%CI 1.24–3.53).  
These findings suggest that there are different groups of IDUs with different 
risk profiles and it may be useful for developing targeted interventions. 
Encouraging pharmacies not only to sell sterile injection equipment to IDUs, as 
a regulated alternative to SEPs, but also to provide linkages to other services, 
may be widely applicable in those areas where injecting drug use is a major 
driving force in HIV transmission. Strategies to expand syringe access should 
be combined with other harm reduction services to make both sources more 
effective and easily utilized. 
 
 
5.5. Pharmacists role in HIV activities  
for IDUs (Paper IV) 
All pharmacists in the focus groups had come into contact with IDUs at their 
workplace. It appeared that pharmacists saw themselves as part of the public 
health system and believed that HIV/AIDS was a serious social and public 
health issue, but held a strongly negative position toward IDUs and against the 
idea of free distribution of clean syringes or other injecting equipment and 
disposal of used syringes in pharmacies. Although selling syringes over-the-
counter is allowed in Estonia, several pharmacist participants refused to sell 
syringes to IDUs. Counselling and health promotion was regarded as one aspect 
of a pharmacist’s work, but there was a strong belief that pharmacies are not the 
right place for HIV/AIDS prevention. However, pharmacists agreed to make 
information leaflets available and inform IDUs about possible services, for 
example to refer them to the nearest SEPs, HIV testing or drug treatment 
centres. Resistance was explained by concerns that IDUs would steal from the 
pharmacy, endanger staff and scare away other customers, but not that syringe 
sales would increase drug use, as has been found previously (Farley et al., 1999; 
Lewis et al., 2002).   
 IDUs stated that pharmacies were convenient for acquiring syringes due to 
their extended opening hours and local distribution; however they have detected 
stigma from pharmacists and other customers. A positive attitude prevailed also 
toward SEPs: all IDUs in our study were aware of their existence and had used 
their services. As for weaknesses of SEPs, respondents mentioned the small 
numbers, limited coverage and operating hours. IDUs stressed the need for 
distilled water which could be sold for one-time administration, and other 
paraphernalia. 
The specific quotes reflecting common attitudes about experiences of 
syringe sale practices in Estonia are presented in Box 1 and suggestions about 




Box 1. Experiences of syringe sale practices in pharmacies 
Pharmacists:  
Quotation 1: "...Many pharmacies do not sell syringes any more, it is better to lose 
two junkies than all your customers..."  
Quotation 2: "...Our price policy is that a syringe costs [a high price]. We do not get 
so many addicts that it would disturb our normal work routine..." 
Quotation 3: "...I sell syringes, but I am selective about whom I sell to, there is a 
very big difference who is buying  ...." 
 
IDUs: 
Quotation 4: "… We will buy syringes here, on the spot, when we need them... Who 
will go so far?…" 
Quotation 5: "…Exchange points are open at certain times. But what do you do in 
the evening? You go to a pharmacy that is open 24 h, but they do not sell syringes to 
you..." 
Quotation 6: "…You go to a pharmacy, want to buy syringes and they tell that we do 
not sell syringes. All in all, they want to get rid of you, because you are an addict. 
But other people can buy syringes without any problems..."  
 
Box 2. Suggestions about the involvement of pharmacies in HIV prevention  
Pharmacists:  
Quotation 1: "…We are not against informational materials, these could be placed 
on a separate table and anyone interested can take them...." 




Quotation 3: “…Distilled water is needed, it plays a big part. Just in small 
ampules…” 
Quotation 4: “…At a reasonable price, around a kroon, there would be plenty of 
buyers for this kit (containing syringe, needle, water, filter, sterile sponge)…” 
 
 
The results from both the pharmacists and IDUs are valuable for understanding 
barriers and the potential improvement of harm reduction within pharmacies in 
Estonia. There are no formal or legislative obstacles for providing HIV pre-
vention services for IDUs at pharmacies. Providing services to IDUs within 
pharmacy settings is contingent upon pharmacists and their staff receiving 
professional development trainings that cultivate sensitivity towards the needs 
and experiences of IDUs. Continuous education of pharmacists on drug use, 
HIV prevention issues and practical guidance on how to work/counsel an IDU 
client can remove some barriers. Pharmacists should be engaged in developing 
appropriate interventions, and selecting pharmacists who are motivated to work 
with IDUs and/or pharmacists from high drug use areas who could give the 
most benefit and allow positive experiences to build.   
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6. GENERAL DISCUSSION 
 
Drug abuse is a significant problem in Estonia, associated with several health 
and social problems, which warrants attention on policy-makers level with the 
help of public health professionals to revise existing measures and find the best 
strategies for effective responses to this situation. Although there is no single or 
universal solution to the drug problem there are a number of evidence-based 
interventions to input into drug policy.  
This thesis refers that there are distinct subgroups among people who inject 
drugs and who may need specific interventions. Adolescent risk-taking is a 
significant public health concern. Interventions to delay initial tobacco and 
alcohol use and to reduce the rapid transition to drug use including injecting 
drug use could have substantial public health benefits. Further development of 
the Estonian existing drug education program is needed. It should meet the 
attributes of evidence based knowledge with taking into account the actual 
situation surrounding youth drug use. Also should be suitable for the students' 
age and containing a detailed division of different issues by lessons and school 
stages. More attention should be paid at school level to selective prevention: to 
develop guidelines for coping with drug-related cases, prevention work with 
risk-group students and cooperation with organisations outside schools. Also 
family and parenting programs have demonstrated the effectiveness in reducing 
the onset of drug use (Babor et al., 2010). Similarly environment and classroom 
management programs, and teaching social or life skills, have shown a positive 
impact on adolescent behavior (Babor et al., 2010). Such interventions would 
need to focus on relatively young adolescents. 
Based on the findings in order to help problem drug users to reduce the 
consequences of their drug use, the substitution of non-injecting drug use for 
injecting drug use may be a potentially important new method for reducing HIV 
transmission through multi-person use of drug injection equipment. Inter-
ventions promoting alternatives to injecting with social marketing campaigns to 
reinforce the positive identity of non-injectors and different treatment options to 
encourage reverse transition or short-term prescribing to lower the tolerance 
could be used in HIV prevention programs (Pates et al., 2005). In the presence 
of a high prevalence of injecting drug use and high HIV prevalence among 
IDUs in Estonia, there is a need for a comprehensive approach to find additional 
sources for acquiring syringes besides SEPs. One option could be engaging 
pharmacies in high drug use areas and /or pharmacists willing to be public 
health educators to expand syringe access in combination with other harm 
reduction interventions. Altogether, further expanding syringe exchange 
programs by improving the quality of services offered is helpful. 
In addition, interventions which have been effective in reducing risk 
behavior and harm among drug users are: methadone and buprenorphine 
maintenance, heroin substitution, opiate antagonists (e.g. naltrexone depot 
formulation), SEPs, antiretroviral therapy, HIV counseling and testing, psycho-
social treatment, peer self-organizations, naloxone distribution (primarily for 
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opiate users with high risk of overdose) and brief interventions in general 
medical settings (Babor et al., 2010; Dutta et al., 2012). A recent review 
revealed that the combination of SEPs, medication-assisted therapy, anti-
retroviral therapy and HIV counseling with testing in combination with 
expansion and high effectiveness yield in reduced HIV incidence and reduced 
levels of future morbididty, mortality and healthcare costs (Dutta et al., 2012). 
There are also resources available offering data through the Cochrane Collabo-
ration, EXASS Network provided by Pompidou Group, EMCDDA`s best 
practice portal and European Harm Reduction Network, useful for policy 
makers in the areas of drug-related prevention, treatment, social reintegration 
and harm reduction.   
Given the severity of injecting drug use problem, Estonia would benefit from 
a consistent strategy regulating drug policy with the monitoring and evaluation 
of the actions. From an evidence based perspective, evaluation is an important 
tool for demonstrating possible effects or unintended consequences and 
necessary for forward planning (Pompidou Group & European Comission 
2012). While drug policy will be regulated under the National Health Strategy 
addressing a wide-range of topics, it may entail loss of focus from drug related 
problems and delay of implementing necessary actions. 
In conclusion, despite the efforts already made the existing drug policy 
measures and interventions should be reevaluated to make necessary 
amendments and formulation of new approaches to scale-up of harm reduction 
interventions. Under limited resources the evaluations of quality of inter-
ventions through developed quality control criteria are essential. Basing drug 
policy on scientific evidence will not eliminate drug use or the problems related 
to drug injecting, but reorienting drug policy towards evidence based 
approaches has the potential to reduce harms more effectively and would allow 








1. Early initiation into injecting drug use is related to multiple adverse health 
consequences and doubled risk for HIV seropositivity. Evaluation of current 
preventive programs targeted at adolescents and developing new comprehen-
sive evidence-based interventions to prevent drug use or delay the age of 
starting drug use, including the age of starting to inject drugs is crucial in 
Estonia. In addition there is a need for consistent programmes for youth at 
risk to identify potential risk factors and manage these. 
2. IDUs who engage in non-injecting drug use may be reducing their risk of 
acquiring HIV though sharing injection equipment, but if already infected 
may be a critical group for sexual transmission of HIV to people who do not 
inject drugs. The substitution of non-injecting drug use for injecting drug use 
may be a potentially important new method for reducing HIV transmission 
through multiperson use of drug injection equipment. 
3. IDUs who visit pharmacies represent a subgroup of an earlier stage of IDUs 
and had a lower prevalence of HIV than SEP users. Strategies to expand 
syringe access should be combined with other harm reduction interventions 
to make both sources of syringes more effective and easily used. 
4. Pharmacists reported a readiness to sell syringes to IDUs, however, negative 
attitudes toward IDUs were identified as important factors restricting such 
sales. IDUs stated that pharmacies were convenient for acquiring syringes 
due to their extended opening hours and local distribution. Addressing 
negative attitudes through educational courses and involving pharmacists 
willing to be public health educators in high drug-use areas would improve 
access for HIV prevention services for IDUs. Pharmacies could be utilized 
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SUMMARY IN ESTONIAN 
 
Uimastite tarvitamise riskitegurid ja kahjude vähendamise  
teenused süstivatele narkomaanidele Eestis:  
soovitused uimastipoliitika korraldamiseks 
Kõikidest uimastite tarvitajatest ei saa regulaarseid tarvitajaid ja nad ei pruugi 
jääda sõltuvusse. Samas ei ole täpselt teada, miks mõnele tähendab uimastite 
tarvitamine järjest süvenevat protsessi, teisele mitte. On leitud, et uimastite 
tarvitamise alustamist mõjutavad enamasti sotsiaalsed tegurid, kuid probleemne 
tarvitamine on põhjustatud valdavalt psühholoogilistest mõjuritest (Frisher jt 
2007). Süstimise alustamise riskitegurid võivad olla sotsiaaldemograafilised või 
individuaalsed, näiteks sugu (sagedasem meeste hulgas), vanus (≤16 aastat), 
koolist väljalangemine, kanepi ja crack´i suitsetamine, süstiva seksuaalpartneri 
olemasolu, kaasatus prostitutsiooni ning kokkupuude vägivallaga (Fuller jt 
2001, Fuller jt 2002, Miller jt 2006, Neaigus jt 2001, Pates jt 2005, Van 
Ameijden jt 1994, Van Ameijden jt 2001). Samuti on süstimisele üleminek 
tõenäolisem regulaarse ja pikaajalise kokaiini, heroiini või trankvillisaatorite 
tarvitajatel (Van Ameijden jt 1994, Van Ameijden jt 2001). Süstimisele 
üleminekut võivad mõjutada ka tugevama toime vajadus või soodsam hind (ehk 
sama toime madalama hinnaga) (Bravo jt 2003).   
On leitud, et ühe ja sama narkootikumi erinevate manustamisviisidega 
kaasnevad ka erinevad riskid, kuigi tarvitamise sagedus ja annus jäävad samaks 
(Pates jt 2005). Mittesüstivatel narkomaanidel on väiksem risk nakatuda vere 
kaudu levivatesse haigustesse, väiksem üledoosi oht ja vähem probleeme 
sõltuvussündroomiga. Neil ei esine ka ägedaid või kroonilisi terviseprobleeme, 
mis süstimisega kaasnevad. Üldiselt mõjutab narkootikumide manustamise viisi 
kaks tegurit: peamine manustamisviis narkomaani sotsiaalses keskkonnas ning 
narkoturg, mis määrab kättesaadava aine tüübi (Pates jt 2005). Enamasti 
minnakse lahjematelt uimastitelt üle kangematele ja mittesüstimiselt süsti-
misele. Protsessi kirjeldab lävepakuteooria (ingl k gateway effect), mille järgi 
narkootikumide tarvitamisele eelneb suitsetamine ja alkoholi pruukimine, 
alustatakse kanepiga ning seejärel minnakse üle tugeva toimega narkootiku-
midele (Kandel ja Faust 1975). 
Eestis on hinnanguliselt 13 000 süstivat narkomaani, mis moodustab 
ligikaudu 2,4% täiskasvanud elanikkonnast (15–44-aastased) (Uusküla jt 
2007a). Ida- ja Lääne-Euroopa  riikide võrdlus näitab, et süstiv narkomaania on 
enam levinud just Venemaal ja Eestis (Mathers jt 2010). Süstivad narkomaanid 
on peamiselt noored (keskmiselt 24–27-aastased) vene keelt kõnelevad mehed, 
kes elavad Tallinnas ja Ida-Virumaal (Lõhmus jt 2008, Lõhmus jt 2011, 
Uusküla jt 2005, Uusküla jt 2011). Uimastite süstimine koos süstimisvarustuse 
jagamisega on põhjustanud Eestis HIV-epideemia: eri uuringute hinnangul on 
40–90% süstivatest narkomaanidest HIV-positiivsed (Platt jt 2006, Uusküla jt 
2005, Uusküla jt 2007b, Wilson jt 2007). HIV-nakkuse kandjate arv Eestis on 
tõenäoliselt üle 10 000, samuti on Eestis registreeritud uute HIV-juhtude määr 
50 
kõrgeim Euroopas (UNAIDS 2011). Eesti narkoturu peamisteks narkootiku-
mideks on fentanüül (77%) ja amfetamiin (23%). Kiirelt väljakujuneva 
sõltuvuse ja suure üledoosiohu tõttu peetakse fentanüüli üheks ohtlikumaks 
narkootiliseks aineks. Fentanüüli süstimine on seotud suurema HIV levimuse 
ning seda soodustava riskikäitumisega – süstla ja muu süstimisvarustuse 
jagamise ning riskialti seksuaalkäitumisega (Talu jt 2010).  
Kirjeldatud olukord viitab jätkuvale vajadusele ennetavate ja kahjusid 
vähendavate teenuste järele. Ennetustegevused peaksid piirama eelkõige uimas-
tite tarvitamise (sh süstimise) alustamist ja olema suunatud eri sihtrühmadele: 
noortele; mittesüstivatele narkomaanidele, et selgitada süstimisega kaasnevaid 
ohte; ning süstivatele narkomaanidele, et takistada süstimise levikut nende 
lähikondsete hulgas (Pates jt 2005). Piiramaks HI-viiruse, B- ja C-hepatiidi ning 
muude vere kaudu edasikanduvate haiguste levikut, propageeritakse süstivatele 
narkomaanidele steriilse süstimisvarustuse (süstlad, nõelad jm) kasutamist. 
Siiani on see toimunud valdavalt süstlavahetusprogrammide kaudu. Meetodi 
edukus sõltub selle vastavusest narkomaani vajadustele, mistõttu tuleks puhta 
süstimisvarustuse hankimiseks pakkuda erinevaid võimalusi (Coffin 2000; 
Obadia jt 1999). Üks võimalusi süstlavahetusprogrammide kõrval on süstla-
vahetus apteekides, mille edukust on rahvusvaheliselt tõendatud (Lurie jt 1998, 
Sheridan jt 1996, Thein jt 2003, USAID 2012). Apteegid on korraldanud nii 
steriilse süstimisvarustuse jagamist, kasutatud süstalde kogumist, meta-
doonasendus- ja võõrutusravi kui ka nakatumisest hoidumise ja uimastite 
ohutuma tarvitamise õpetamist (Matheson jt 2002, Sheridan jt 1996, Strang jt 
1996, USAID 2012). 
Eeltoodust lähtuvalt oli töö üldeesmärk hinnata uimastite tarvitamist, riski-
käitumist ja kahjude vähendamise teenuste kasutamist süstivate narkomaanide 
hulgas ning võimalike uute kahjude vähendamise teenuste rakendamisvajadust 
Eestis. 
 
Uurimistöö erieesmärgid olid järgmised: 
1. kirjeldada uimastite tarvitamise alustamist süstivate narkomaanide seas ning 
välja selgitada süstimise varajase alustamise mõju edasisele riskikäitumisele 
ning HIVi levimusele (I publikatsioon);  
2. uurida seoseid uimastite eri manustamisviiside ja HIV-serostaatuse vahel 
ning välja selgitada seonduvad sotsiaaldemograafilised tegurid, eri 
manustamisviiside mõju uimastite tarvitamise riskiteguritele ja seksuaal-
käitumisele süstivate narkomaanide seas (II publikatsioon); 
3. välja selgitada riskikäitumise esinemine ja HIVi levimus ning hinnata 
kahjude vähendamise teenuste kasutamist ja vajadust nendel süstivatel 
narkomaanidel, kes hangivad süstlaid peamiselt apteekidest, ja nendel, kes 
teevad seda süstlavahetusprogrammi kaudu (Tallinna näitel) (III 
publikatsioon);  
4. uurida nii apteekrite kui ka süstivate narkomaanide arvamusi, mis 
puudutavad apteekrite kaasatust HIVi ennetamisse süstivate narkomaanide 
seas, hinnata apteekrite võimalusi pakkuda süstivatele narkomaanidele 
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kahjude vähendamise teenuseid ning välja selgitada võimalikud takistused, 
mis võivad piirata süstalde müüki ja kahjude vähendamise teenuste 




Käesolev uurimistöö põhineb kahel läbilõikeuuringul (publikatsioonid I, II ja 
III) ja kahel kvalitatiivsel uuringul (publikatsioonid II ja IV). 
2007. ja 2009. aastal Tallinnas korraldatud läbilõikeuuringutes osales 
vastavalt 350 ja 331 süstivat narkomaani. Uuritavate leidmiseks rakendati 
uuritavate poolt uuringusse kaasamise meetodit. Uuringutes osalemise 
kriteeriumid olid järgmised: vanus vähemalt 18 aastat, vene või eesti keele 
oskus, narkootikumide süstimine viimase kahe kuu jooksul ning võimelisus 
anda teadlik nõusolek. Iga uuritavaga tehti anonüümne intervjuu, et koguda 
andmeid sotsiaaldemograafilise tausta, süstiva narkomaania, seksuaalse 
riskikäitumise, kriminaalse tausta ning narkomaaniaravi kogemuse kohta. 
Samuti võeti vereproov HIV-vastaste antikehade leidmiseks. 
Kvalitatiivsete uuringute käigus intervjueeriti 16 süstivat narkomaani (II 
publikatsioon) ning seejärel 19 apteekrit ja 15 süstivat narkomaani (IV publikat-
sioon). Fookusgruppide intervjueerimisel kasutati poolstruktureeritud küsimus-
tikku. II publikatsiooni koostamiseks koguti teavet järgmiste küsimuste kohta: 
(1) missuguseid uimasteid tarvitatakse, (2) kuidas erinevaid uimasteid 
manustatakse ning (3) miks mõned süstivad narkomaanid eelistavad ja kasu-
tavad narkootikumide manustamise viisina ainuüksi süstimist. IV publikatsiooni 
koostamiseks koguti teavet järgmistel teemadel: (1) olemasolevad puhaste 
süstalde saamise kohad ja suhtumine süstlavahetusprogrammi, (2) süstlade 
ostmine apteekidest ning sellekohased arvamused ja kogemused, (3) soovitused 
apteekide kaasamiseks ennetustegevustesse ja kahjude vähendamise teenus-
tesse. Intervjuud fookusgruppidega tehti eesti ja vene keeles, intervjuud 
lindistati ning hiljem transkribeeriti. Andmed kategoriseeriti alakategooriatesse, 
mis järgnevalt kodeeriti eesmärgiga kaardistada uuritava nähtuse omadused, et 
kirjeldada ja seletada antud nähtust. 
 
 
Tulemused ja arutelu 
Tulemustest selgus, et süstimisega alustatakse keskmiselt 18-aastaselt (vahe-
mikus 9–42 eluaastat). Ligikaudu veerand uuritavatest vastas, et on alustanud 
süstimist nooremalt kui 15-aastaselt. Väga noori (alla 15-aastaseid) süstimisega 
alustanuid oli kõige rohkem aastatel 1996–2000, praeguseks on nende osakaal 
mõnevõrra langenud ja stabiliseerunud. Väga noorelt alustanute hulgas oli 
rohkem madala haridustasemega isikuid ja töötuid ning nende riskikäitumise 
tõenäosus oli suurem. Kõnealune uuritavate grupp oli märkimisväärselt varem 
hakanud suitsetama ja alkoholi proovima, samuti olid nad kaks korda suurema 
tõenäosusega HIV-positiivsed (kohandatud analüüsi põhjal).  
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Kirjeldatud tulemused näitavad, kuivõrd olulised on sekkumised, mis 
takistavad või lükkavad edasi uimastite tarvitamise alustamist. Noorte käitumise 
mõjutamisel on efektiivseks osutunud laiaulatuslike ennetusprogrammide ellu-
viimine koolides võimalikult madalas õppeastmes, perekondade kaasamine ja 
lähikonnapõhised sekkumised (Babor jt 2010, Du Rant jt 1999, Kokkevi jt 2006). 
On teada, et sageli võib lapsel või noorukil koos sõltuvusprobleemiga 
esineda depressioon, hüperaktiivsus, ärevushäire, keskendumisraskus või mõni 
muu psüühiline probleem, mis on viinud sõltuvusprobleemi tekkeni (Deas 2006, 
Shier jt 2003). Seetõttu on väga oluline probleemi varajane märkamine ning last 
ümbritsevate inimeste oskus probleemi ära tunda ja suunata laps vajaliku abini 
(eeldusel, et see on olemas ja kättesaadav). 2011. aastal uuriti Eestis alaealiste 
uimastisõltlaste tervishoiu- ja tugiteenuste vajadusi. Uurimistulemused näitasid 
alaealistele mõeldud ravikohtade vähesust ja pikki järjekordi, mis pärsivad 
alaealise probleemidele lahenduse leidmist. 
Samuti on teada, et osa süstivatest narkomaanidest eelistab uimasteid tarvitada 
ainult süstimise teel ning osa neist kasutab teisi manustamisviise. Antud väitekirja 
analüüsist selgus, et narkomaanid, kes süstimise kõrval lisaks teisi manustamis-
viise kasutasid, olid 50% võrra vähema tõenäosusega HIV-positiivsed. Samas olid 
nad seksuaalselt aktiivsemad: neil oli enam seksuaalpartnereid ning nad olid 
sagedamini nakatunud seksuaalsel teel levivatesse haigustesse. Teiste 
manustamisviiside propageerimisega võib kaasa aidata HIVi leviku piiramisele 
nende süstivate narkomaanide seas, kes ei ole veel nakatunud. Samas HI-
viirusega nakatunud, kes on seksuaalselt aktiivsemad, vajaksid enam HIVi ja 
teiste suguhaiguste testimise võimalusi, samuti ravi ja nõustamist. Uuemate 
teadusuuringute põhjal on teada, et antiretroviirusravi varajane alustamine võib 
vähendada HI-viirusega nakatumist seksuaalsel teel (Cohen jt 2011). 
Selleks, et piirata HI-viiruse levikut süstivate narkomaanide seas, on Eestis 
rakendatud mitmesuguseid kahjude vähendamise teenuseid, enamasti süstla-
vahetust ja metadoonasendusravi. Üks võimalusi laiendada ennetusprogramme 
ning jõuda paremini sihtgrupini on apteekide kaasamine, mis on andnud häid 
tulemusi paljudes riikides, sh USAs, Inglismaal, Šotimaal, Austraalias ja Uk-
rainas (Deren jt 2003; Lurie jt 1998; Matheson jt 2002; Thein jt 2003; USAID 
2012). Apteegid on korraldanud näiteks steriilsete süstalde müümist, juhen-
danud nakkushaigustest hoidumist ja uimastite ohutumat tarvitamist, jaganud 
süstimisvarustust ning pakkunud metadoonasendus- ja võõrutusravi (Matheson 
jt 2002; Sheridan jt 1996, Sheridan jt 2007; Strang jt 1996).  
Intervjuudest süstivate narkomaanidega selgus, et puhtaid süstlaid saadakse 
peamiselt apteekidest või süstlavahetusprogrammi kaudu. Analüüsi tulemused 
näitasid, et süstivad narkomaanid, kes hankisid puhtaid süstlaid enamasti 
apteekidest, olid veel nii-öelda algajad ning süstlavahetusprogrammi eelistaja-
tega võrreldes oli nende hulgas vähem ka HIV-positiivseid. Tulemus lubab 
arvata, et apteekide kaasamine aitaks leida kontakti süstivate narkomaanidega, 
kellel võib-olla puudub kokkupuude asjakohaste riiklike teenustega ning 
võimaluse korral suunata neid teenuste juurde. 
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Süstalde hankimise koht sõltub selle lähedusest ja mugavusest. Fookusgrupis 
osalenud süstivate narkomaanide sõnul ei ole süstlavahetuspunkte piisavalt, 
mistõttu võiksid sarnaseid teenuseid pakkuda ööpäeva läbi avatud apteegid. 
Enamik apteekritest oli nõus müüma narkomaanidele steriilseid süstlaid, aitamaks 
piirata nakkushaiguste levikut. Apteekrite suhtumine süstivatest narkomaanidest 
klientidesse oli kahetine. Narkomaanide toime pandud vargused olid põhjustanud 
negatiivse suhtumise, samas peegeldus vastustest mõistmine, et need on haiged 
inimesed, kes vajavad abi. Apteekrite negatiivset suhtumist leevendaksid 
mõnevõrra koolitused, mis õpetavad narkomaanidega suhtlema, vallandamata 
nende agressiivset käitumist. Samuti vajaksid apteekrid rohkem teavet riikliku 
ennetustegevuse ja kahjude vähendamise teenuste kohta. Koostöö apteekritega 
aitaks luua lisavõimalusi narkomaanide riskikäitumise vähendamiseks. Hinnata 
tuleb ka apteegi klientide valmisolekut ja nõusolekut. Elanikkonna nõusolekut 
soodustaks asjakohane teavitamine ja teenuste läbimõeldud korraldus, näiteks 




1. Väga varajane (15-aastaselt ja nooremalt) süstimise alustamine põhjustab 
mitmeid terviseriske, sh kaks korda suuremat riski nakatuda HI-viirusega. 
Eestis on vaja hinnata olemasolevaid noortele suunatud ennetusprogramme 
ning välja töötada uusi laiaulatuslikke tõenduspõhiseid ennetusprogramme, 
et vältida või edasi lükata narkootikumide tarvitamise alustamist noorte seas. 
Samuti on vaja süsteemseid ja järjepidevaid sekkumisi sagedasema riski-
käitumisega noorte mõjutamiseks.  
2. Süstivatel narkomaanidel, kes kasutavad uimastite tarvitamisel ka teisi 
manustamisviise, on väiksem risk nakatuda HI-viirusega. Samas nakatununa 
võivad nad kujuneda riskirühmaks, kes kannab viiruse seksuaalsel teel 
üldrahvastikku. Süstimise asendamine muu manustamisviisiga võib 
vähendada HI-viirusega nakatumist süstivate narkomaanide hulgas. 
3. Süstivad narkomaanid, kes hangivad puhtaid süstlaid peamiselt apteekidest, 
on tõenäoliselt lühema süstimise “karjääriga”. Samuti on HI-viirusega 
nakatunuid nende hulgas vähem kui narkomaanide seas, kes hankisid puh-
taid süstlaid peamiselt süstlavahetusprogrammi kaudu. Kahjude vähen-
damise teenuste (sh süstlavahetusteenuse) laiendamine hõlbustaks vajaliku 
abi kättesaadavust süstivatele narkomaanidele.  
4. Apteekrid olid valmis müüma narkomaanidele puhtaid süstlaid, kuid teatud 
juhtudel võib negatiivne suhtumine osutuda takistuseks. Süstivad narko-
maanid leidsid, et apteekide eelis süstlavahetuspunktide ees on apteekide 
suurem hulk ja pikemad lahtiolekuajad. Apteekrite negatiivset suhtumist 
aitaksid leevendada koolitused süstiva narkomaania olemuse, ennetus-
tegevuste ja kahjude vähendamise teenuste kohta. Koostöö apteekritega, kes 
oleksid nõus osalema riskikäitumist vähendavate teenuste pakkumisel, aitaks 
luua vajalikke lisavõimalusi, et piirata HIVi ja teiste vere kaudu edasi-
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